SEC Form 4 · accession 0001209191-15-049816
TETRAPHASE PHARMACEUTICALS INC · TTPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Guy Macdonald
Officer — President and Chief Executive · Director
Period of report
Jun 1, 2015
Accepted (ET)
Jun 3, 2015 · 6:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001373707
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 1, 2015 | M | 10,000 | $7.94 | A | 81,087 | D | |
| Common StockF1,F3 | Jun 1, 2015 | S | 10,000 | $41.86 | D | 71,087 | D | |
| Common Stock | Jun 1, 2015 | S | 1,087 | $41.98 | D | 70,000 | D | |
| Common Stock | Jun 1, 2015 | M | 20,000 | $0.87 | A | 90,000 | D | |
| Common StockF4 | Jun 1, 2015 | S | 5,000 | $41.92 | D | 85,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F5 | $7.94 | Jun 1, 2015 | M | 10,000 | D | — | May 14, 2023 | Common Stock | 10,000 | 210,000 | D |
| Employee Stock Option (right to buy)F6 | $0.87 | Jun 1, 2015 | M | 5,000 | D | — | Sep 10, 2019 | Common Stock | 5,000 | 84,323 | D |
| Employee Stock Option (right to buy)F6 | $0.87 | Jun 1, 2015 | M | 15,000 | A | — | Sep 10, 2019 | Common Stock | 15,000 | 69,323 | D |
Explanation of responses
- F1The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2014.
- F2The amount of securities beneficially owned by the reporting person following the transaction reported on this Form 4 reflects the purchase by the reporting person of 550 shares of common stock on May 14, 2015 pursuant to the issuer's 2014 Employee Stock Purchase Plan.
- F3The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $41.20 to $43.52 per share. The reporting person herby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission,the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $41.88 to $41.93 per share. The reporting person herby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission,the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5Vests as to 25% of the original number of shares granted on 5/15/2013 and further vests as to an additional 6.25% of the original number of shares granted at the end of each successive three-month period thereafter until 5/15/2017.
- F6Fully vested.